DIRS.INFO The most relevant business & tech news

"Its permission to make products using propylene glycol (PG) is cancelled, and it is allowed to make and sell all other products." The Marion factory in Uttar Pradesh was closed in March, after an analysis last year by Uzbekistan's health ministry of two cough syrups made by Marion, Ambronol and DOK-1 Max. India's pharmaceuticals department told parliament that tests had also shown that a sample of propylene glycol (PG), an ingredient of cough syrups taken from Marion's factory contained EG. Reuters has reported that DEG and EG have been used by unscrupulous actors as a substitute for propylene glycol because they are cheaper. Uzbek state prosecutors told a court in Tashkent that distributors of the contaminated Marion syrups paid officials a bribe of $33,000 to skip mandatory testing there.

Persons: Anushree, Shashi Mohan Gupta, Gupta, Rajeev Singh Raghuvanshi, Marion, syrups, Marion syrups, Krishna N, Saurabh Sharma, Clarence Fernandez Organizations: Marion Biotech, Emenox, REUTERS, Reuters, World Health Organization, WHO, EG, Thomson Locations: Uzbekistan, Noida, India, DELHI, Uttar Pradesh, Gambia, Cameroon, Marion, Ambronol, Tashkent

The company, Marion Biotech, bought the ingredient — propylene glycol (PG) — from trader Maya Chemtech India, as reported by Reuters. "Marion bought commercial-grade propylene glycol," said a second source, an investigator, who declined to be named while the inquiry is ongoing. International standards allow only trace amounts of EG and DEG in pharmaceutical-grade propylene glycol. The toxins were found in cough syrups exported to Gambia by the other Indian company, Maiden Pharmaceuticals. India made it mandatory for companies to have their cough syrups tested before export from June.

Persons: Marion, Deepak Sharma, Max, Vijay Kumar, Tuhin Bhattacharya, Mool Singh, Atul Rawat, Jaya Jain, Sachin Jain, Rohan Gupta, syrups, Maiden, Saurabh Sharma, Krishna, Jennifer Rigby, Olzhas, Sara Ledwith, Michele Gershberg, Deepa Babington Organizations: Reuters, Marion Biotech, Indian, EG, World Health Organization, Authorities, . Police, Marion, Court, Maya, Maiden Pharmaceuticals, WHO, Thomson Locations: DELHI, Uzbekistan, India, Delhi, Marion, Uttar Pradesh, Allahabad, Gambia, Indonesia, London, Almaty

☆ Exclusive: India may issue alert on Marion cough syrup exports after toxins found
▼ + stars: | 2023-03-04 | by ( Krishna N. Das | ) www.reuters.com time to read: +3 min

[1/2] Logo of Marion Biotech, a healthcare and pharmaceutical company is seen on a gate outside their office in Noida, India, December 29, 2022. REUTERS/Anushree FadnavisNEW DELHI, March 4 (Reuters) - India may issue an alert on cough syrup exported by Marion Biotech, whose products have been linked to deaths in Uzbekistan, after tests showed many of the company's drug samples contained toxins, a drug inspector said on Saturday. "The health ministry could issue an alert. Babbar has been part of a team that inspected Marion's plant four times after Uzbekistan said in December the children died after consuming the company's cough syrups. India in October suspended production at Maiden for violating manufacturing standards after the WHO said four of its cough syrups may have killed dozens of children in Gambia.

Two Marion directors were "out of the country and will be arrested as soon as they land in India," senior police official Ram Badan Singh told Reuters. Uzbekistan in December said the children died after consuming Marion's cough syrups. The same toxin was found in cough syrups exported to Gambia by another Indian company, Maiden Pharmaceuticals. India in October suspended production at Maiden for violations of manufacturing standards after the World Health Organization said four of its cough syrups may have killed dozens of children in Gambia. The deaths in Gambia and Uzbekistan have dented the image of the $41 billion pharmaceutical industry in India, which is known as the "pharmacy of the world."

☆ Indian maker of cough syrup linked to Uzbekistan deaths halts production
▼ + stars: | 2022-12-30 | by ( ) www.reuters.com time to read: +2 min

NEW DELHI, Dec 30 (Reuters) - The Indian maker of a cough syrup that was linked to the death of 19 children in Uzbekistan said on Friday that it had halted production of all medicines after an inspection by the drug regulator. Indian media reported that the inspectors had found deviation from rules on manufacturing at one of Marion Biotech's units. Uzbekistan's health ministry said at least 18 children died in Samarkand city after consuming Marion Biotech's Dok-1 Max syrup. Hasan Harris, Marion Biotech's legal head, told Reuters partner ANI, "We await the reports, the factory was inspected. The Uzbekistan case follows deaths of at least 70 children in Gambia that had been linked to cough and cold syrups manufactured by New Delhi-based Maiden Pharmaceuticals Ltd.

Search resuls for: "Ambronol"

5 mentions found